Dan Pham, MD
Internal Medicine · Falls Church, VANPI 1518313659
Payments from drug & device makers
Across 493 payments — averaging $56.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$11K
- Amgen$8K
- Novo Nordisk$1K
- Gilead$984
- Bayer$749
- Pfizer$724
- plus $5K from 27 others
What the payments were for
- Speaking & faculty fees$14,35051%
- Travel & lodging$2661%
- Food & beverage$13,20047%
- Education$900%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 68 | $11,324 |
| Amgen | 54 | $7,600 |
| Novo Nordisk | 41 | $1,326 |
| Gilead | 35 | $984 |
| Bayer | 21 | $749 |
| Pfizer | 43 | $724 |
| Sumitomo Pharma America, Inc. | 50 | $594 |
| Astellas Pharma US Inc | 19 | $541 |
| Lilly USA, LLC | 22 | $515 |
| AbbVie | 16 | $456 |
| Verona Pharma, Inc. | 18 | $407 |
| Boehringer Ingelheim | 14 | $394 |
| Merck | 7 | $220 |
| Baxter Healthcare | 5 | $213 |
| Viiv Healthcare Company | 4 | $191 |
| Ferring Pharmaceuticals Inc. | 8 | $190 |
| Tempus AI, Inc | 5 | $185 |
| Shield Therapeutics Inc | 10 | $173 |
| Exact Sciences | 7 | $158 |
| Abbott | 7 | $149 |
| Viatris Specialty LLC | 7 | $127 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $119 |
| Kowa Pharmaceuticals America, Inc. | 7 | $114 |
| Hologic Sales And Service, LLC | 5 | $110 |
| Agios Pharmaceuticals, Inc. | 3 | $69 |
| RGH Enterprises LLC | 2 | $52 |
| Vertex | 2 | $48 |
| Phadia US Inc. | 2 | $42 |
| Organon | 1 | $30 |
| Mylan Specialty L.p. | 1 | $30 |
| Dexcom, Inc. | 1 | $25 |
| Scilex Pharmaceuticals Inc. | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$27,906 in reported general payments places this provider in the 95th percentile of 2,724 internal medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 539 | $472,396 |
| JardianceEmpagliflozin | 393 | $329,310 |
| RybelsusSemaglutide | 144 | $194,171 |
| KerendiaFinerenone | 253 | $185,400 |
| VemlidyTenofovir Alafenamide | 83 | $136,168 |
| EliquisApixaban | 66 | $73,397 |
| JanuviaSitagliptin Phosphate | 69 | $72,254 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 103 | $72,095 |
| ProliaDenosumab | 29 | $50,215 |
| MyrbetriqMirabegron | 74 | $49,848 |
| TrulicityDulaglutide | 32 | $47,465 |
| JanumetSitagliptin Phos/Metformin Hcl | 50 | $42,032 |
| GemtesaVibegron | 46 | $40,629 |
| MounjaroTirzepatide | 38 | $40,285 |
| LinzessLinaclotide | 28 | $34,063 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere | $11,324 | $544,491642 claims |
| Boehringer IngelheimJardiance, Jentadueto, Tradjenta, Synjardy Xr | $394 | $398,695467 claims |
| Novo NordiskRybelsus, Ozempic | $1,326 | $203,741155 claims |
| BayerKerendia | $749 | $185,400253 claims |
| MerckJanuvia, Janumet, Janumet Xr | $220 | $137,374141 claims |
| GileadVemlidy | $984 | $136,16883 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $515 | $87,75070 claims |
| PfizerEliquis | $724 | $73,39766 claims |
| AmgenProlia | $7,600 | $50,21529 claims |
| Astellas Pharma US IncMyrbetriq | $541 | $49,84874 claims |
| AbbVieLinzess, Namzaric | $456 | $45,69740 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $594 | $40,62946 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 internal medicine providers in Virginia.
Other internal medicine in Falls Church
- Amit MahajanFalls Church$1.3M
- Kevin DonohueFalls Church$655K
- Anu GeorgeFalls Church$547K
- Sheinei AlanFalls Church$352K
- Leroy VaughanRichmond$20.8M
- James ClarkCharlottesville$16.2M
- Nabil AndrawisBurke$8.5M
- Mary BlumbergNorfolk$6.5M
- David RamstadSuffolk$5.8M
- Andrew PoklepovicRichmond$4.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.